+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
P

Actively Recruiting

Researchers are studying muscle invasive bladder cancer to see if combining pembrolizumab, a type of immunotherapy, with radiation therapy after chemotherapy can help patients avoid bladder removal surgery. This phase II trial focuses on patients who have responded well to initial chemotherapy and aims to improve three-year bladder intact event-free survival. The study also evaluates survival rates, recurrence, and treatment side effects in participants. Participants receive photon beam radiation therapy once daily from Monday to Friday for up to 20 treatments. Pembrolizumab is given intravenously on the first day of each 21-day cycle, continuing for up to 18 cycles or about 12 months if there is no disease progression or unacceptable side effects. Before treatment, participants undergo a transurethral resection of bladder tumor TURBT and provide tissue samples. Imaging scans such as CT, MRI, or PET, along with cystoscopy and collection of urine and blood samples, are performed throughout the study. During the study, participants are closely monitored with regular assessments including imaging and questionnaires about symptoms. Follow-up visits occur every 26 weeks until two years after treatment and then annually up to five years. Researchers measure outcomes like bladder intact event-free survival, local recurrence, metastasis-free survival, overall survival, and rates of salvage cystectomy. Safety and treatment-related symptoms are tracked carefully, and specimens are collected for future research.

Age: 18Years +All GendersPhase 2
182 locations
S

Actively Recruiting

Researchers are evaluating biomarkers to predict how patients with stage IIIB-IV non-small cell lung cancer NSCLC respond to first-line immunotherapy using PD1 or PD-L1 based treatments and to guide second-line treatment choices. This phase II trial explores how changes in circulating tumor DNA ctDNA in the blood may help identify treatment failure early and personalize therapy. The study also investigates second-line immunotherapies for patients whose cancer progresses, including treatments targeting specific genetic mutations. Participants first receive PDL1-based immunotherapy with or without chemotherapy every three weeks for up to 12 to 24 months. Those who respond well after 12 months may either stop or continue therapy up to 24 months under different study arms. After 24 months, patients may stop or continue treatment based on disease status. Patients with disease progression enter a second phase receiving second-line immunotherapy regimens such as tremelimumab with durvalumab or adagrasib with bevacizumab. Treatments are given according to specific schedules and continue unless disease worsens or side effects occur. Throughout the study, participants undergo regular blood sampling to measure ctDNA, imaging tests including CT, MRI, or PET scans, and may have tumor biopsies and fluid collections as part of routine care. After treatment ends, follow-up occurs at 30 days, then every three months for a year, and every six months up to two years. The main outcomes measured include progression-free survival during first and second-line treatments, overall survival, ctDNA changes, treatment response, and safety events. This trial helps improve personalized treatment strategies for advanced NSCLC.

Age: 18Years +All GendersPhase 2
13 locations
S

Actively Recruiting

Researchers are evaluating a treatment approach for patients with locally advanced cervical cancer that has spread to nearby tissues or lymph nodes. This phase III trial compares the addition of induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before the usual chemotherapy and radiation treatment combined with pembrolizumab, followed by pembrolizumab maintenance. The study aims to determine if adding induction therapy improves progression-free survival and overall survival, while assessing safety and biomarkers related to treatment response. Participants are randomly assigned to one of two groups. One group receives standard chemoradiation with cisplatin and pembrolizumab followed by pembrolizumab maintenance. The other group receives induction chemotherapy with carboplatin, paclitaxel, and pembrolizumab before starting chemoradiation and pembrolizumab maintenance. Chemoradiation includes weekly cisplatin, radiation therapy daily for 5 weeks, and brachytherapy treatments. Pembrolizumab is given intravenously at different intervals during the treatment and maintenance phases. Throughout the study, participants undergo various imaging scans such as PET, CT, chest x-ray, and MRI, along with blood sample collections to monitor their condition. Researchers evaluate outcomes including progression-free survival, overall survival, treatment side effects, treatment completion times, and biomarker levels. After completing treatments, participants are followed up every 3 months for 2 years, then every 6 months for 3 more years to monitor long-term effects and disease status.

Age: 18Years +FEMALEPhase 3
346 locations
C

Actively Recruiting

Researchers are studying patients with stage II-IV colorectal cancer CRC that can be removed by surgery to compare two blood tests, the Haystack MRD test and the Signatera assay, for detecting if the cancer returns after treatment. The study aims to find if the Haystack test can detect cancer recurrence earlier and more sensitively than the currently used Signatera test. Early detection of cancer return is important to improve chances for curative treatment in these patients. Participants will provide tissue and blood samples before surgery and then undergo both Haystack MRD and Signatera ctDNAcfDNA testing several times after surgery. Testing occurs 3 to 10 weeks post-surgery, then every 3 months for the first two years, and every 6 months for years three to five if no disease progression is observed. The study also explores the performance of two additional cancer detection assays under development. Throughout the study, participants will have blood samples collected at regular intervals and archival tissue accessed for personalized testing. Researchers will monitor minimal residual disease rates, the timing of cancer recurrence detection by the tests and imaging, and associations between ctDNA results and recurrence status over a follow-up period of up to five years. This long-term monitoring aims to assess the clinical performance and lead time advantages of the Haystack test compared to Signatera.

Age: 18Years +All GendersPhase Not Applicable
13 locations
E

Actively Recruiting

Researchers are evaluating the use of botensilimab and balstilimab, two immunotherapy drugs, given before surgery to treat advanced colorectal cancer that can be surgically removed. This phase II trial focuses on patients with mismatch repair proficient or microsatellite stable colorectal cancer, aiming to see if these drugs can improve disease-free survival and reduce tumor size prior to surgery. The study also investigates safety, pathologic responses, quality of life, and other outcomes. Participants receive botensilimab intravenously on day 1 and balstilimab intravenously on days 1, 15, 29, and 43 if there is no disease progression or unacceptable side effects. Surgery to remove the cancer is performed 5 to 16 weeks after treatment. Throughout the study, patients undergo CT or MRI scans and blood sample collections to monitor tumor response and other biological markers. After treatment and surgery, participants are followed for up to three years with visits at 2 and 4 weeks, then every 3 months for 2 years, and every 6 months for an additional year. Researchers monitor disease-free survival, recurrence, adverse events, quality of life, and the timing of surgery. Blood tests and imaging help assess tumor changes and detect molecular recurrence to better understand long-term outcomes.

Age: 18Years +All GendersPhase 2
11 locations
P

Actively Recruiting

Researchers are conducting a phase 3, randomized, double-blind study to evaluate the effectiveness of Ivonescimab combined with mFOLFOX6 versus Bevacizumab combined with mFOLFOX6 for the first-line treatment of metastatic colorectal cancer. The trial includes patients who have not previously received systemic therapy for metastatic disease and aims to compare these treatments in a controlled setting. Participants will be randomly assigned to one of two treatment groups Ivonescimab plus mFOLFOX6 or Bevacizumab plus mFOLFOX6. Both treatments are given by intravenous infusion every two weeks for up to eight cycles. After these initial treatment cycles, maintenance therapy with Ivonescimab or Bevacizumab combined with Leucovorin and 5-Fluorouracil will be administered every two weeks for up to two years. Throughout the study, participants will undergo regular assessments to monitor disease progression using standardized imaging criteria. Researchers will evaluate progression-free survival as the primary outcome over approximately 2.5 years, alongside secondary outcomes including overall survival, tumor response rate, duration of response, and adverse events over up to 4 years. Study-related care and follow-up will be conducted during this period to assess treatment effects and safety.

Age: 18Years +All GendersPhase 3
243 locations

1-10 of 19

1